iQure Pharma, a Princeton, NJ-based biotech company, raised $600K in Early Closing as part of its Series A funding.
The round was led by Keiretsu Mid-Atlantic, together with business angels associated with Keiretsu’s Accelerator Fund and the Keiretsu North-West chapter.
The company intends to use the funds for research into neuropathic pain compounds.
Led by Coo Pawel Zolnierczyk, iQure Pharma is focused on the development of therapeutics for neuropathic pain, epilepsy, and wider neurodegenerative diseases. The company aims to advance the preclinical development novel therapeutics iQ-007 and iQ-008. In particular, iQ-007 has demonstrated positive results in NIH ETSP tests, which show that the compound has the ability to treat pain, epilepsy, and potentially neurodegenerative diseases. Additionally, iQ-008 has progressed within the NIH PSPP program focused on pain. iQ-008, a novel analgesic compound, is progressing to the next stage in the Preclinical Screening Platform for Pain (PSPP), which has been set up under the HEAL initiative to facilitate the identification of potential non-addictive treatments for acute and chronic pain conditions and alternatives to opioid analgesics.
FinSMEs
31/08/2022